ANTIPSYCHOTICS- CLASSIFICATION, USES, AND ADVERSE EFFECTS by Mohammed Abdulhakim  Hamad Al Hattab , Abdulkhaliq Yahya Mansour Alahmari, Maan Ahmed Alsaaid , Batool Abed Mansoor Ahmed , Malak Saleh Abdullah, Khalid Ali Alharbi , Asma Salem Almatrafi  , Nouf Al-Abdulmohsin, Waleed Mohammed Mujalli , Nasser Mansour Khawaji
IAJPS 2018, 05 (12), 15690-15695        Mohammed Abdulhakim  Hamad Al Hattab et al          ISSN 2349-7750 
 
 
 
w w w . i a j p s . c o m  
 
Page 15690 
 
        CODEN [USA]: IAJPBB                        ISSN: 2349-7750 
 
  INDO AMERICAN JOURNAL OF 
 PHARMACEUTICAL SCIENCES 
                              
Available online at: http://www.iajps.com                                      Review Article 
ANTIPSYCHOTICS- CLASSIFICATION, USES, AND ADVERSE 
EFFECTS 
Mohammed Abdulhakim  Hamad Al Hattab 1 , Abdulkhaliq Yahya Mansour Alahmari 2 , 
Maan Ahmed Alsaaid 3 , Batool Abed Mansoor Ahmed 4 , Malak Saleh Abdullah 2 , Khalid 
Ali Alharbi 5 , Asma Salem Almatrafi 6 , Nouf Al-Abdulmohsin 7 , Waleed Mohammed 
Mujalli 8 , Nasser Mansour Khawaji 8 
1 New Najran General Hospital,2 King Khalid University,3 Arabian Gulf University,4 Misr 
University For Science and Technology,5 Qassim University,6 Umm Al-Qura University,7 King 
Faisal University,8 Alaml and Psychiatric Hospital, Jazan 
Abstract: 
Introduction: Antipsychotic agents are categorized usually as either “typical antipsychotics” or “atypical 
antipsychotics”. Typical antipsychotic pharmacological agents, which are also called first-generation 
antipsychotics or traditional antipsychotics, include chlorpromazine and haloperidol. On the other hand, atypical 
antipsychotic pharmacological agents, which are also called second generation antipsychotics, include risperidone, 
quetiapine, and olanzapine. Both typical and atypical antipsychotics work in similar mechanisms by inhibiting the 
activation of specific receptors in the dopamine pathway.Aim of work: In this review, we will discuss the 
antipsychotics- classification, uses, and adverse effects, Methodology: We did a systematic search for 
antipsychotics- classification, uses, and adverse effects using PubMed search engine (http://www.ncbi.nlm.nih.gov/) 
and Google Scholar search engine (https://scholar.google.com). All relevant studies were retrieved and discussed. 
We only included full articles.Conclusions: The prescription of atypical antipsychotic agents, like quetiapine and 
olanzapine, has been significantly increasing and in many conditions, they are sometimes prescribed “off-label” – 
which is a worrying trend due to their possible risk of developing harmful adverse events. Therefore, atypical 
antipsychotic agents must only be used in their specific indications and with caution, especially among older 
patients and young adults. Atypical antipsychotic agents can be indicated for schizophrenia treatment and other 
associated conditions and in some cases to treat the behavioral and psychological manifestations related to 
dementia (risperidone only). Antipsychotics are not first-line treatments for patients with anxiety and are not 
generally recommended for the use in patients with posttraumatic stress disorder or insomnia. 
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INTRODUCTION: 
Antipsychotic agents are categorized usually as either 
“typical antipsychotics” or “atypical antipsychotics”. 
Typical antipsychotic pharmacological agents, which 
are also called first-generation antipsychotics or 
traditional antipsychotics, include chlorpromazine 
and haloperidol. On the other hand, atypical 
antipsychotic pharmacological agents, which are also 
called second generation antipsychotics, include 
risperidone, quetiapine, and olanzapine. Both typical 
and atypical antipsychotics work in similar 
mechanisms by inhibiting the activation of specific 
receptors in the dopamine pathway. However, 
atypical agents are less often associated with 
extrapyramidal adverse events, which are strongly 
correlated with the use of old typical agents. On the 
other hand, atypical agents, along with typical agents, 
are linked with serious adverse events, indulging 
diabetes mellitus, cerebrovascular events and 
cardiovascular mortality [1]. In this paper, we will 
review the recent advances on antipsychotics- 
grouping, uses, and adverse events.  
 
Antipsychotic agents are generally used in providing 
therapy for patients with schizophrenia and 
associated conditions and in some other cases to 
manage behavioral and psychological manifestations 
related to dementia (specifically risperidone). Global 
experience indicates that antipsychotic agents are 
being increasingly indicated for use in off-label cases 
like anxiety and insomnia [2]. The use of atypical 
antipsychotic agents has been increasing in many 
parts of the world and it is probably that off-label use 
is an important factor in this wide increase. Special 
Authorities usually put restrictions on prescribing 
antipsychotics but these have been removed recently 
on olanzapine prescription. Risperidone (both depot 
injection and tablets) and quetiapine antipsychotics 
have also been available for use without restriction 
since the year 2008. 
 
Classically, primary care physicians are responsible 
for writing prescriptions for patients, once an 
antipsychotic agent has been started by a psychiatrist 
after making a diagnosis of a case like schizophrenia. 
If a primary care physician wants to start treatment, 
then it is best to only prescribe the drug in the 
presence of classical recognized manifestations and 
to discuss the therapy with a psychiatrist prior to 
prescribing. It is also important for physicians to be 
highly cautious when prescribing these agents for 
elderly patients, young individuals and those at 
higher risk of cardiovascular disease, mainly due to 
increase weight, diabetes mellitus or elevated 
cholesterol. 
 
METHODOLOGY: 
We did a systematic search for antipsychotics- 
classification, uses, and adverse effects using 
PubMed search engine 
(http://www.ncbi.nlm.nih.gov/) and Google Scholar 
search engine (https://scholar.google.com). All 
relevant studies were retrieved and discussed. We 
only included full articles. 
The terms used in the search were: antipsychotics, 
classification, uses, and adverse effects. 
 
Adverse effects of atypical antipsychotics 
Most adverse events are common with the use of all 
antipsychotic agents, including both typical 
antipsychotics and atypical antipsychotics, but can 
occur in different degrees for each pharmacological 
agent. Common dose-dependent adverse events 
usually include: 
• Sedation:  
Mainly seen with olanzapine, clozapine, and 
quetiapine. 
• Anticholinergic effects: 
These include constipation, dry mouth, and 
blurred vision, and are mainly seen with 
olanzapine and clozapine. 
• Dizziness and postural hypotension: 
Mainly seen with risperidone, clozapine, and 
quetiapine. 
With the significantly increasing use of these 
pharmacological agents, many adverse events related 
to the use of atypical antipsychotic agents have been 
reported, like diabetes mellitus, metabolic syndrome, 
obesity, higher risk of cerebrovascular events 
(especially in older patients), higher risk of 
cardiovascular mortality, seizures and tardive 
dyskinesia.3 These adverse events have also been 
reported with the use of typical antipsychotic agents. 
 
Metabolic adverse events: 
Metabolic adverse events, which are linked to the use 
of antipsychotic agents, are of special concern due to 
the increasing cardiovascular morbidity and 
mortality. Olanzapine and clozapine have been 
specifically linked to significant increase in weight, 
dyslipidaemia and hyperglycaemia. Patients using 
these agents usually report a continuous hunger 
sensation. Weight gain can be very high and up to a 
gain of two kilograms in a period of 2 weeks, which 
needs a review of the medication use. All patients 
who have been prescribed an antipsychotic must be 
educated on diet and lifestyle interventions and 
observed for the development of diabetes.4 
 
 
IAJPS 2018, 05 (12), 15690-15695        Mohammed Abdulhakim  Hamad Al Hattab et al          ISSN 2349-7750 
 
 
 
w w w . i a j p s . c o m  
 
Page 15692 
Extrapyramidal effects 
Atypical antipsychotic agents are usually thought to 
lead to the development of less extrapyramidal 
adverse events when compared to typical 
antipsychotic agents. A previous meta-analysis 
concluded that olanzapine, clozapine, and risperidone 
are significantly less likely to cause extrapyramidal 
manifestations when compared to low potency 
typical antipsychotic agents (like chlorpromazine).5 
Most of studies have concluded that there are no 
significant differences between members of the 
atypical group regarding extrapyramidal effects [3]. 
 
Monitoring requirements for clozapine 
Patients who are using clozapine need close 
observation as clozapine can lead to the development 
of neutropenia, which may progress to a potentially 
serious agranulocytosis. Blood investigations 
(including WBCs count and absolute neutrophil 
count) are important [6]: 
• 10 days before initiating therapy. 
• Every week for eighteen weeks of therapy 
• Every 4 weeks after that an until the end of 
therapy. 
• 4 weeks following discontinuation of the 
drug. 
• Following discontinuation of the drug due to 
abnormal results, until levels return to 
normal 
Patients who develop any evidence of infection, like 
sore throat, fever or flu-like manifestations will need 
urgent CBD. Patients must also be educated to report 
any such manifestations. 
 
Other adverse events include constipation which is 
usually linked to the use of clozapine and can 
sometimes be serious and potentially fatal. The co-
prescription of a laxative agent among patients who 
are receiving clozapine is routinely recommended. 
Other adverse events of clozapine use can be similar 
to adverse events of other antipsychotic agents, but 
antimuscarinic side effects (like dry mouth, blurred 
vision, and urinary retention), sedation and increased 
weight can usually be more obvious. The 
concomitant use of some medicines may significantly 
increase the rate of adverse events due to: 
 
• The potential risk for developing bone marrow 
suppression, especially with the use of drugs like 
trimethoprim, nitrofurantoin, co-trimoxazole, 
sulphonamides, and carbamazepine. 
• The elevation of plasma concentrations of 
clozapine, especially with the use of drugs like 
erythromycin and ciprofloxacin. 
Tardive dyskinesia 
Incidence of new-onset tardive dyskinesia following 
the use of antipsychotics has been found to be about 
three percent with the use of risperidone and one or 
two percent with the use of other atypical 
antipsychotic agents. Generally, tardive dyskinesia 
can potentially develop in about twenty percent of 
patients who are receiving therapy with typical 
antipsychotic agents [7]. Tardive dyskinesia is 
considered to be of special concern because it might 
not be clear immediately, is usually not sensitive to 
treatment, might be permanent and might progress 
even if treatment stops. 
 
Atypical antipsychotics for the treatment of 
schizophrenia and related disorders: 
Patients who are diagnosed with schizophrenia must 
usually be treated by a multidisciplinary team of 
physicians, which should include both primary care 
and secondary care. The early diagnosis and prompt 
management of a first schizophrenia episode is 
crucial as this could significantly benefit prognosis 
and potentially even the progression of the disease 
[8]. 
 
Typical antipsychotic agents and atypical 
antipsychotic agents are usually used for the 
management and treatment of schizophrenia. Both 
types of antipsychotic agents have been linked to the 
development of adverse events with the presence of a 
significant variation in each patient’s response to 
therapy. Therefore, the same pharmacological agent 
cannot be administrated for each patient. Generally, 
an antipsychotic agent is initiated at a relatively low 
dose and then carefully increased to prevent or 
decrease the rate of adverse events. 
Some guidelines recommend the administration of an 
atypical antipsychotic agent as the first treatment 
choice in patient with schizophrenia due to their 
relatively low risk of developing extrapyramidal 
adverse events when compared to the administration 
of typical antipsychotic agents. On the other hand, 
this recommendation has been assessed recently 
following the increasing concerns of developing 
metabolic adverse events with the use of atypical 
antipsychotic agents, which could be more serious on 
chronic use [9]. 
Clozapine is generally recommended in patients who 
have treatment resistance, after the patient has 
already attempted at least 2 other antipsychotic 
agents. This pharmacological agent cannot be 
prescribed in primary care settings, but primary care 
providers can have an important role in the 
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monitoring for the development of adverse events. 
Pharmacological therapies for patients with 
schizophrenia must always be used in accordance to 
comprehensive psychosocial interventions. 
 
Atypical antipsychotics for the treatment of 
behavioural and psychological symptoms of 
Dementia 
Behavioral and psychological manifestations of 
dementia include; aggressiveness, disturbance in 
activities and psychotic malfunctions. Non-
pharmacological therapy is advised as a first-line, but 
in severe cases pharmacological treatment can be 
used to treat dementia. Risperidone is considered to 
be the only atypical antipsychotic agent that is 
approved for the administration in patients with 
dementia. Antipsychotic agents usually achieve 
relatively few benefits for patients with dementia and 
in some cases; they can have higher potential of 
developing serious adverse events. A recent study 
estimated that for every one hundred patients who 
have dementia and are using an antipsychotic, only 
twenty will show benefits but there will be one death 
and one cerebrovascular event [10]. 
Atypical antipsychotic agents must be used with great 
caution in the elderly, because of the higher incidence 
and prevalence of developing adverse events and 
should only be used in cases with severe clinical 
manifestations. The decision to administrate an 
antipsychotic agent must be discussed with the 
patient, the family and the caregivers. Initial doses of 
the agent must be decreased to at least half the usual 
dose or even less, with considering other factors like 
the weight of the patient, the presence of additional 
comorbidities, and the concomitant use of other 
pharmacological agents. Treatment must also be 
regularly monitored and reviewed. Antipsychotic 
therapy is not considered to be effective for the 
treatment of symptoms like wandering, social 
withdrawal, irritability, pacing, touching, cognitive 
dysfunction and incontinence. Patients who have any 
of these symptoms might respond to other 
interventions like environment improvements.11 
 
Off-label uses of atypical antipsychotics:  
In a recent study that was conducted in Canterbury, 
more than ninety-six percent of psychiatrists were 
found to prescribe antipsychotic agents for different 
off-label uses. Quetiapine was found to be the most 
commonly prescribed antipsychotic in these cases. 
The 3 most common causes for off-label 
administration of quetiapine were: anxiety (in up to 
89 percent of cases), sedation (in about 79 of cases) 
and posttraumatic stress disorder (in about 57 of 
cases). Overall, it is thought that between forty 
percent and seventy percent of atypical antipsychotic 
agents are prescribed for off-label uses. It is 
commonly accepted that there is few evidence 
present to support antipsychotics prescription for off-
label uses, but this practice is becoming more 
widespread and there no sufficient guidance as to 
whether it needs to be decreased, or if patients are 
really getting benefits from using these 
pharmacological agents in addressing these 
indications [12]. 
Marketing done by drug companies has a significant 
role in the elevation of rates of use of antipsychotic 
agent within the last years. In the US, 2 drug 
companies settled out of court, after getting a charge 
for illegally advertising for the off-label use of 
olanzapine and quetiapine [13], 18 Off-label use of 
antipsychotics is considered to be legal in many 
countries, making the prescription of atypical 
antipsychotic agents possible in patients with 
indications like anxiety. However, the physician who 
prescribe such pharmacological agents must be 
careful in weighing up potential harms and benefits 
and must also consider other appropriate 
pharmacological agents (or even non-
pharmacological interventions) prior to prescribing 
an antipsychotic. The decision to use an antipsychotic 
must be thoroughly discussed with the patient and 
their family members and with careful documentation 
of all the details in the patient’s notes. 
When dealing with patients who have anxiety, the use 
of a selective serotonin re-uptake inhibitor is 
considered to be the step in the treatment. 
Psychological therapy, like cognitive behavioral 
therapy, is equally beneficial. Patients must be treated 
for twelve weeks prior to the assessment of benefit of 
SSRIs. Therapy might require to be continued for 
other six to twelve months following the resolution of 
anxiety manifestations [14]. 
There are few evidences suggesting that quetiapine 
antipsychotic might be beneficial as an intervention 
in cases of generalized anxiety disorder. However, 
because of potentially serious adverse events that are 
associated with the use of quetiapine, it must be only 
administrated for short-term anxiety therapies and 
only of if other appropriate pharmacological 
therapies or psychological interventions had been 
attempted and failed. 
 
Post-traumatic stress disorder (PTSD) 
PTSD is a psychiatric condition in which the patient 
will develop manifestations following the exposure to 
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traumatic events. Three clusters of manifestations are 
classically found: re-experiencing the unpleasant 
event, avoidance and hyperarousal. Interventions in 
patients with PTSD include a combination of 
psychological interventions, administration of 
pharmacological agents and providing sufficient 
social support. The first choice of pharmacological 
agents is generally an antidepressant, usually an 
SSRI. There is not enough evidence to recommend 
the use of quetiapine antipsychotic (or any other 
antipsychotic agent) for PTSD treatment [15]. 
Insomnia often occurs secondary to an underlying 
etiology like another disease or poor sleep hygeine. 
Management and treatment of the underlying 
etiology will most likely improve insomnia. The first 
and best management is improving “sleep hygiene”. 
This is achieved by educating the patients to avoid 
excess alcohol, nicotine and caffeine use, avoid any 
stimuli at night, avoid staying in bed when not trying 
to sleep and learning relaxation techniques. If these 
interventions do not resolve the insomnia, 
pharmacological interventions can be considered only 
for short-term use. Zopiclone or shorter-acting 
benzodiazepines can be good choices. This is 
recommended with using the lowest possible dose 
and for the shortest duration [16].  Antidepressants 
are not generally recommended for patients with 
insomnia unless there is associated depression or 
anxiety.Quetiapine antipsychotic is not generally 
recommended for insomnia treatment unless there is 
another psychiatric condition like schizophrenia. 
Quetiapine has been found to improve total sleep 
duration and sleep efficiency but adverse events like 
abnormal leg movements and restlessness are 
considered to be significant limitations for its use 
[17]. 
 
CONCLUSIONS: 
The prescription of atypical antipsychotic agents, like 
quetiapine and olanzapine, has been significantly 
increasing and in many conditions, they are 
sometimes prescribed “off-label” – which is a 
worrying trend due to their possible risk of 
developing harmful adverse events. Therefore, 
atypical antipsychotic agents must only be used in 
their specific indications and with caution, especially 
among older patients and young adults. Atypical 
antipsychotic agents can be indicated for 
schizophrenia treatment and other associated 
conditions and in some cases to treat the behavioral 
and psychological manifestations related to dementia 
(risperidone only). Antipsychotics are not first-line 
treatments for patients with anxiety and are not 
generally recommended for the use in patients with 
posttraumatic stress disorder or insomnia. 
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